Family History
455 articles
Triple Immunotherapy Shows Dramatic Results
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.
Finding More Targets for Pancreatic Cancer Treatment
Dr. Noelle LoConte discusses a clinical trial for cancer patients, including pancreatic cancer patients, that have an NRG1 gene fusion.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
New Guidelines on the Use of Radiation for Pancreatic Cancer Treatment
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
Solving the Mystery of Cachexia
Researchers are looking for ways to combat cachexia, the metabolic syndrome that causes weight and muscle loss in people with cancer and other diseases.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.